Low-risk group
Based on current ESMO-ESGO-ESTRO 2016 risk groups, patients with
low-risk EC should not undergo LND as part of the staging
process(25) (Table 3). In the low-risk group,
considering there is a very low (0.8%) associated risk of LN
metastasis(26,27), there is a need to consider the
short and long-term morbidities of LND(14,24).
However, a minority of studies suggest detection of occult LN metastasis
is essential for prognosis, as 4.1–5.6% of low-risk EC patients may
have LN metastasis(13,28). LNs are one of the most
common sites of relapse, with ∼90% patient
mortality(29). LND can provide better prognostic
information on patients with low-risk EC at risk of disease recurrence,
improving outcomes(29).